Tiziana Life Sciences公布新生物标志物数据：鼻用Foralumab可下调非活动性继发进展型多发性硬化症伴隐匿性残疾进展患者脑脊液炎症、上调神经保护通路，并与PET扫描中显示的小胶质细胞活化减少相关

美股速递02-25

Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。

这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能通过调节中枢神经系统的免疫环境，为这类难治性多发性硬化症患者带来新的希望。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1139368419?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-25 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139368419","market":"us","top_or_hot":-1,"title":"Tiziana Life Sciences公布新生物标志物数据：鼻用Foralumab可下调非活动性继发进展型多发性硬化症伴隐匿性残疾进展患者脑脊液炎症、上调神经保护通路，并与PET扫描中显示的小胶质细胞活化减少相关","media":"美股速递","content":"<p>Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。</p>\n<p>这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能通过调节中枢神经系统的免疫环境，为这类难治性多发性硬化症患者带来新的希望。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tiziana Life Sciences公布新生物标志物数据：鼻用Foralumab可下调非活动性继发进展型多发性硬化症伴隐匿性残疾进展患者脑脊液炎症、上调神经保护通路，并与PET扫描中显示的小胶质细胞活化减少相关</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiziana Life Sciences公布新生物标志物数据：鼻用Foralumab可下调非活动性继发进展型多发性硬化症伴隐匿性残疾进展患者脑脊液炎症、上调神经保护通路，并与PET扫描中显示的小胶质细胞活化减少相关\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-25 20:11 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。\n这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1139368419","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139368419","pubTimestamp":1772021463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。\n这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能通过调节中枢神经系统的免疫环境，为这类难治性多发性硬化症患者带来新的希望。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","TLSA":"Tiziana Life Sciences PLC"},"translate_title":"Tiziana Life Sciences announces new biomarker data: Nasal Foralumab can down-regulate cerebrospinal fluid inflammation in patients with inactive secondary progressive multiple sclerosis with occult disability progression, upregulate neuroprotective pathways, and correlate with reduced microglial activation shown in PET scans Associated with","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLSA":1},"content_text":"Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。\n这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能通过调节中枢神经系统的免疫环境，为这类难治性多发性硬化症患者带来新的希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139368419","isCrawlerRequest":true}